Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience

References

• EAU guidelines: Management of PSA-only recurrence after treatment with curative intent. Available from: https://uroweb.org/guideline/prostate-cancer/#6_3. 2021.
   Google Scholar
• Bjartell A, Bottai M, Persson J, et al. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scand J Urol. 2016;50(4):255–259. Aug
   PubMed Web of Science ®Google Scholar
• Lars J Petersen LJ, Zacho HD. Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer. Scand J Urol. 2017;51(6):498–501. Dec
   PubMed Web of Science ®Google Scholar
• Rauscher T, Maurer AJ, Beer FP, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57(11):1713–1719.
   PubMed Web of Science ®Google Scholar
• Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926–937.
   PubMed Web of Science ®Google Scholar
• Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–863.
   PubMed Web of Science ®Google Scholar
• Ploussard G, Gandaglia G, Borgmann H, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol. 2019;76(4):493–504.
   PubMed Web of Science ®Google Scholar
• Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67(2):299–309.
   PubMed Web of Science ®Google Scholar
• Fossati N, Suardi N, Gandaglia G, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol. 2019;75(1):176–183.
   PubMed Web of Science ®Google Scholar
• Bravi CA, Fossati N, Gandaglia G, et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol. 2020;78(5):661–669.
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453.
   PubMed Web of Science ®Google Scholar
• Devos G, Muilwijk T, Raskin Y, et al. Comparison of peri-operative and early oncological outcomes of robot-assisted vs. open salvage lymph node dissection in recurrent prostate cancer. Front Oncol. 2019;9:781.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Gandaglia G, Fossati N, et al. Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer. Eur. Urol. 2017;72(3):432–438.
   PubMed Web of Science ®Google Scholar
• Siriwardana A, Thompson J, van Leeuwen PJ, et al. Initial multicenter experience of (68) gallium-PSMA PET/CT guided robotassisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int. 2017;120(5):673–681. Nov
   PubMed Web of Science ®Google Scholar
• Linxweiler J, Saar M, Al-Kailani Z, et al. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: perioperative and early oncological outcomes. Surg Oncol. 2018;27(2):138–145.
   PubMed Web of Science ®Google Scholar
• Abreu F, Fay C, Park D, et al. Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series . BJU Int. 2017;120(3):401–408.
   PubMed Web of Science ®Google Scholar
• Schuster DM, Nanni C, Fanti S, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55(12):1986–1992.
   PubMed Web of Science ®Google Scholar
• Giesel FL, Hadaschik B, Cardinale J, J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–688.
   PubMed Web of Science ®Google Scholar
• Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518–526.
   PubMed Web of Science ®Google Scholar
• Linxweiler J, Sprenk J, Cascetta K, et al. Robotic salvage lymph node dissection in recurrent prostate cancer: lessons learned from 68 cases and implications for future clinical management. J Urol. 2021;206(1):88–96.
   PubMedGoogle Scholar
• Welch HG, Albertsen PC. Reconsidering prostate cancer mortality - the future of PSA screening. N Engl J Med. 2020;382(16):1557–1563.
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781–1788.
   PubMed Web of Science ®Google Scholar
• De Bruycker A, Spiessens A, Dirix P, et al. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20(1):406.
   PubMed Web of Science ®Google Scholar
• Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650.
   PubMed Web of Science ®Google Scholar
• Uppal A, Wightman SC, Mallon S, et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015;6(6):3540–3552.
   PubMedGoogle Scholar